Blog entry by Meguid El Nahas

Anyone in the world

Interesting pilot study on the effect of the anti-inflammatory agent pirfenidone in patient with diabetic nephropathy. The study shows that over 12 months low dose pirfenidone (1200mg/d) improved GFR compared to placebo and high dose (2400mg/d). The drug had no effect on proteinuria. Whilst the number of patients in this study was very small and the drop out rate high due to side effects, the data are of interest as if confirmed they would add a therapeutic option in diabetic nephropathy. These data goes along those observed in experimental models and in a small study of patients with FSGS. Clearly, a phase 3 RCT is needed to confirm if this intervention has potential benefits in patients with diabetic nephropathy.

[ Modified: Thursday, 1 January 1970, 1:00 AM ]